Mizuho Securities Buyers of Biohaven Pharmaceutical (BHVN) on Weakness

Mizuho Securities analyst Vamil Divan reiterated a Buy rating and $85.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN), saying they are buyers on weakness.

The analyst commented, "Biohaven has released mixed topline data for their Phase 2/3 study of troriluzole in obsessive compulsive disorder (OCD). The drug missed the primary endpoint but did show a trend to benefit, especially in patients with more severe disease. The company plans to move forward with a larger Phase 3 program, but we expect investor focus on the stock to remain squarely on the strong progress they appear to making with Nurtec ODT. OCD represents ~$2 to our BHVN DCF, and our recent investor sentiment survey suggests the stock will see some modest downward pressure today, but we expect Nurtec ODT to continue to exceed expectations and thus would be buyers on any weakness."

For an analyst ratings summary and ratings history on Biohaven Pharmaceutical Holding click here. For more ratings news on Biohaven Pharmaceutical Holding click here.

Shares of Biohaven Pharmaceutical Holding closed at $68.94 yesterday.

You May Also Be Interested In

• Biohaven Pharma (BHVN) PT Raised to $23 at RBC Capital
• Securitize Corp (SECZ) PT Lowered to $10 at Benchmark as Stock Plummets Post Q2 Earnings
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30